بیماریهای خود ایمنی و بارداری: مرور روایتی

نوع مقاله : مقاله مروری

نویسندگان

1 گروه مامایی، واحد کازرون، دانشگاه آزاد اسلامی، کازرون، ایران

2 دانشجوی دانشکده پرستاری و مامایی، کمیته تحقیقات دانشجویی دانشگاه علوم پزشکی شهرکرد، شهرکرد، ایران

10.22038/nnj.2023.64702.1346

چکیده

مقدمه و هدف: در سال های اخیر گام های بلندی در زمینه بیماری های خودایمنی برداشته شده است. در مقاله حاضر، به مرور روایتی بیماریهای خودایمنی در بارداری می پردازیم .
مواد و روش ها: یافته های مقاله مرور روایتی حاضر از طریق جستجو در سایت های معتبر پزشکی شامل پابمد، اسکوپوس، وب آو ساینس و استفاده از موتور جستجوی گوگل اسکولار بدون محدودیت زمانی تا انتهای سال 2021 میلادی با کلید واژه های "بیماری خود ایمنی و بارداری" حاصل گردید. معیار ورود مقالات انگلیسی زبان در زمینه بیماری های خود ایمن با شیوع یا عوارض بیشتر در بارداری بود. معیار خروج عدم دسترسی به مقاله کامل، مستنداتی شامل کامنتری و نامه به سردبیر بود. نتایج بدست آمده از عنوان و چکیده مقالات توسط دو ارزیاب بررسی شدند.
یافته ها: این دسته از بیماری­ها تابلو بالینی متفاوتی را در بارداری نشان می دهند. برخی بهبودیافته، برخی دیگر بدون تغییر باقی مانده و تعدادی هم تشدید می گردند. واکنش بیماریهای خودایمنی به تغییرات هورمونی و ایمونولوژیک بارداری نشان دهنده پاتوفیزیولوژی متفاوت هر بیماری است. مشاوره­ی صحیح با متخصصین مربوطه، نقطه راه حل مناسب برای این افراد است.
نتیجه گیری: زنان باید در مورد خطرات احتمالی این نوع از بارداری و مصرف برخی داروها در این دوران مطلع شوند. از آنجایی که فعالیت این بیماری در دوران بارداری می تواند مشکل ساز باشد، لذا وجود یک روماتولوژیست در طی این دوران و پس از آن، در کنار متخصصین زنان و زایمان ضرورت می یابد

کلیدواژه‌ها


[1] Cooper GS, Bynum ML, Somers EC. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. Journal of autoimmunity. 2009;33(3-4):197-207.
[2] Cooper GS, Stroehla BC. The epidemiology of autoimmune diseases. Autoimmunity reviews. 2003;2(3):119-25.
[3] Somers EC, Thomas SL, Smeeth L, Schoonen WM, Hall AJ. Incidence of systemic lupus erythematosus in the United Kingdom, 1990–1999. Arthritis Care & Research. 2007;57(4):612-8.
[4] De Carolis S, Moresi S, Rizzo F, Monteleone G, Tabacco S, Salvi S, et al. Autoimmunity in obstetrics and autoimmune diseases in pregnancy. Best Practice & Research Clinical Obstetrics & Gynaecology. 2019;60:66-76.
[5] Khizroeva J, Nalli C, Bitsadze V, Lojacono A, Zatti S, Andreoli L, et al. Infertility in women with systemic autoimmune diseases. Best Practice & Research Clinical Endocrinology & Metabolism. 2019;33(6):101369.
[6] Chighizola CB, Lonati PA, Trespidi L, Meroni PL, Tedesco F. The complement system in the pathophysiology of pregnancy and in systemic autoimmune rheumatic diseases during pregnancy. Frontiers in Immunology. 2020;11:2084.
[7] Desai MK, Brinton RD. Autoimmune disease in women: endocrine transition and risk across the lifespan. Frontiers in endocrinology. 2019;10:265.
[8] Somers EC. Pregnancy and autoimmune diseases. Best Practice & Research Clinical Obstetrics & Gynaecology. 2020;64:3-10.
[9] Oka M. Effect of pregnancy on the onset and course of rheumatoid arthritis. Annals of the rheumatic diseases. 1953;12(3):227.
[10] Lansink M, De Boer A, Dijkmans B, Vandenbroucke J, Hazes J. The onset of rheumatoid arthritis in relation to pregnancy and childbirth. Clinical and experimental rheumatology. 1993;11(2):171-4.
[11] Khashan AS, Kenny LC, Laursen TM, Mahmood U, Mortensen PB, Henriksen TB, et al. Pregnancy and the risk of autoimmune disease. PLoS One. 2011;6(5):e19658.
[12] Guthrie KA, Dugowson CE, Voigt LF, Koepsell TD, Nelson JL. Does pregnancy provide vaccine‐like protection against rheumatoid arthritis? Arthritis & Rheumatism. 2010;62(7):1842-8.
[13] Jørgensen KT, Pedersen BV, Jacobsen S, Biggar RJ, Frisch M. National cohort study of reproductive risk factors for rheumatoid arthritis in Denmark: a role for hyperemesis, gestational hypertension and pre-eclampsia? Annals of the rheumatic diseases. 2010;69(2):358-63.
[14] Merlino LA, Cerhan JR, Criswell LA, Mikuls TR, Saag KG, editors. Estrogen and other female reproductive risk factors are not strongly associated with the development of rheumatoid arthritis in elderly women. Seminars in arthritis and rheumatism; 2003: Elsevier.
[15] Jethwa H, Lam S, Smith C, Giles I. Does rheumatoid arthritis really improve during pregnancy? A systematic review and metaanalysis. The Journal of rheumatology. 2019;46(3):245-50.
[16] Lin H-C, Chen S-F, Lin H-C, Chen Y-H. Increased risk of adverse pregnancy outcomes in women with rheumatoid arthritis: a nationwide population-based study. Annals of the Rheumatic Diseases. 2010;69(4):715-7.
[17] Skorpen CG, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Annals of the rheumatic diseases. 2016;75(5):795-810.
[18] Østensen M, Khamashta M, Lockshin M, Parke A, Brucato A, Carp H, et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis research & therapy. 2006;8(3):1-19.
[19] Flint J, Panchal S, Hurrell A, van de Venne M, Gayed M, Schreiber K, et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding—Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology. 2016;55(9):1693-7.
[20] Aljary H, Czuzoj-Shulman N, Spence AR, Abenhaim HA. Pregnancy outcomes in women with rheumatoid arthritis: a retrospective population-based cohort study. The Journal of Maternal-Fetal & Neonatal Medicine. 2020;33(4):618-24.
[21] Adamczyk-Sowa M, Sowa P, Mucha S, Zostawa J, Mazur B, Owczarek M, et al. Changes in serum ceruloplasmin levels based on immunomodulatory treatments and melatonin supplementation in multiple sclerosis patients. Medical science monitor: international medical journal of experimental and clinical research. 2016;22:2484.
[22] Dobrakowski P, Bogocz M, Cholewa K, Rajchel M, Kapica-Topczewska K, Wawrzyniak S, et al. Month of birth and level of insolation as risk factors for multiple sclerosis in Poland. Plos one. 2017;12(4):e0175156.
[23] Coyle PK. Management of women with multiple sclerosis through pregnancy and after childbirth. Therapeutic advances in neurological disorders. 2016;9(3):198-210.
[24] Mescheriakova JY, Kreft KL, Hintzen RQ. Genetics of multiple sclerosis.  Multiple Sclerosis Immunology: Springer; 2013. p. 197-228.
[25] Miller DH, Fazekas F, Montalban X, Reingold SC, Trojano M. Pregnancy, sex and hormonal factors in multiple sclerosis. Multiple Sclerosis Journal. 2014;20(5):527-36.
[26] Leibowitz U, Antonovsky A, Kats R, Alter M. Does pregnancy increase the risk of multiple sclerosis? Journal of Neurology, Neurosurgery, and Psychiatry. 1967;30(4):354.
[27] Airas L, Saraste M, Rinta S, Elovaara I, Huang YH, Wiendl H, et al. Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells. Clinical & Experimental Immunology. 2008;151(2):235-43.
[28] Bove R, Alwan S, Friedman JM, Hellwig K, Houtchens M, Koren G, et al. Management of multiple sclerosis during pregnancy and the reproductive years: a systematic review. Obstetrics & Gynecology. 2014;124(6):1157-68.
[29] Coyle PK. Multiple sclerosis and pregnancy prescriptions. Expert opinion on drug safety. 2014;13(12):1565-8.
[30] Mohammadi P. Teratogenic Effects of Some Factors on the Human Fetus: A Review study. Journal Mil Med. 2018;19(5):423-31.
[31] Vahedian-Azimi A, Miller AC, Hajiesmaieli M, Kangasniemi M, Alhani F, Jelvehmoghaddam H, et al. Cardiac rehabilitation using the Family-Centered Empowerment Model versus home-based cardiac rehabilitation in patients with myocardial infarction: a randomised controlled trial. Open heart. 2016;3(1):e000349.
[32] Acs N, Bánhidy F, Puhó E, Czeizel AE. Maternal influenza during pregnancy and risk of congenital abnormalities in offspring. Birth Defects Research Part A: Clinical and Molecular Teratology. 2005;73(12):989-96.
[33] Wiesel A, Stolz G, Queisser‐Wahrendorf A. Evidence for a teratogenic risk in the offspring of health personnel exposed to ionizing radiation?! Birth Defects Research Part A: Clinical and Molecular Teratology. 2016;106(6):475-9.
[34] Tavakol H, Farzad K, Fariba M, Abdolkarim C, Hassan G, Seyed-Mostafa H, et al. Hepatoprotective effect of Matricaria chamomilla. L in paraquat induced rat liver injury. Drug research. 2015;65(02):61-4.
[35] Gilbert-Barness E. Teratogenic causes of malformations. Annals of Clinical & Laboratory Science. 2010;40(2):99-114.
[36] Vahedian-Azimi A, Hajiesmaeili M, Amirsavadkouhi A, Jamaati H, Izadi M, Madani SJ, et al. Effect of the Cardio First Angel™ device on CPR indices: a randomized controlled clinical trial. Critical Care. 2016;20(1):1-8.
[37] Afarani MS, Mohammadi M, Shokri MM, Mohammadzadeh S. Investigation of protective effect of Matricaria chamomilla L. Extract on methotrexate-induced hepatotoxicity in Wistar rat. Brazilian Archives of Biology and Technology. 2020;63.
[38] Canti V, Castiglioni MT, Rosa S, Franchini S, Sabbadini MG, Manfredi AA, et al. Pregnancy outcomes in patients with systemic autoimmunity. Autoimmunity. 2012;45(2):169-75.
[39] Marder W, Littlejohn EA, Somers EC. Pregnancy and autoimmune connective tissue diseases. Best Practice & Research Clinical Rheumatology. 2016;30(1):63-80.
[40] Andreoli L, Bertsias G, Agmon-Levin N, Brown S, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Annals of the rheumatic diseases. 2017;76(3):476-85.
[41] Gao R, Zeng X, Qin L. Systemic autoimmune diseases and recurrent pregnancy loss: research progress in diagnosis and treatment. Chinese Medical Journal. 2021;134(17):2140-2.
[42] Braga A, Barros T, Faria R, Marinho A, Rocha G, Farinha F, et al. Systemic Lupus Erythematosus and Pregnancy: a Portuguese Case–Control Study. Clinical Reviews in Allergy & Immunology. 2021:1-9.
[43] Morales-Martínez FA, Salas-Castro C, García-Garza MR, Valdés-Martínez O, García-Luna SM, Garza-Elizondo M, et al. Evaluation of the Ovarian Reserve in Women With Systemic Lupus Erythematosus. Journal of Family and Reproductive Health. 2021:38-44.
[44] Basta F, Fasola F, Triantafyllias K, Schwarting A. Systemic lupus erythematosus (SLE) therapy: the old and the new. Rheumatology and Therapy. 2020;7:433-46.
[45] Jafari AA, Keikha M, Mirmoeeni S, Rahimi MT, Jafari R. Parasite-based interventions on systemic lupus erythematosus (SLE): A systematic review. Autoimmunity Reviews. 2021:102896.
[46] Schreiber K, Hunt BJ. Managing antiphospholipid syndrome in pregnancy. Thrombosis research. 2019;181:S41-S6.
[47] De Carolis S, Tabacco S, Rizzo F, Giannini A, Botta A, Salvi S, et al. Antiphospholipid syndrome: an update on risk factors for pregnancy outcome. Autoimmunity reviews. 2018;17(10):956-66.
[48] Deguchi M, Yamada H, Sugiura-Ogasawara M, Morikawa M, Fujita D, Miki A, et al. Factors associated with adverse pregnancy outcomes in women with antiphospholipid syndrome: a multicenter study. Journal of reproductive immunology. 2017;122:21-7.
[49] Linnemann B. Antiphospholipid syndrome–an update. Vasa. 2018.
[50] Walter IJ, Haneveld MJK, Lely AT, Bloemenkamp KWM, Limper M, Kooiman J. Pregnancy outcome predictors in antiphospholipid syndrome: a systematic review and Meta-analysis. Autoimmunity Reviews. 2021:102901.
[51] CARMONA F, AZULAY M, CREUS M, FÁBREGUES F, PUERTO B, BALASCH J, et al. Risk factors associated with fetal losses in treated antiphospholipid syndrome pregnancies: a multivariate analysis. American Journal of Reproductive Immunology. 2001;46(4):274-9.
[52] Deguchi M, Maesawa Y, Kubota S, Morizane M, Tanimura K, Ebina Y, et al. Factors associated with adverse pregnancy outcomes in women with systematic lupus erythematosus. Journal of Reproductive Immunology. 2018;125:39-44.
[53] Lefkou E, Mamopoulos A, Dagklis T, Vosnakis C, Rousso D, Girardi G. Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy. The Journal of clinical investigation. 2016;126(8):2933-40.
[54] Triolo G, Ferrante A, Ciccia F, Accardo‐Palumbo A, Perino A, Castelli A, et al. Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. Arthritis & Rheumatism. 2003;48(3):728-31.
[55] Ruffatti A, Tonello M, Hoxha A, Sciascia S, Cuadrado MJ, Latino JO, et al. Effect of additional treatments combined with conventional therapies in pregnant patients with high-risk antiphospholipid syndrome: a multicentre study. Thrombosis and haemostasis. 2018;118(04):639-46.
[56] Schreiber K, Breen K, Cohen H, Jacobsen S, Middeldorp S, Pavord S, et al., editors. HYdroxychloroquine to Improve Pregnancy Outcome in Women with AnTIphospholipid Antibodies (HYPATIA) protocol: a multinational randomized controlled trial of hydroxychloroquine versus placebo in addition to standard treatment in pregnant women with antiphospholipid syndrome or antibodies. Seminars in Thrombosis and Hemostasis; 2017: Thieme Medical Publishers.
[57] Tincani A, Andreoli L, Cavazzana I, Doria A, Favero M, Fenini M-G, et al. Novel aspects of Sjögren’s syndrome in 2012. BMC medicine. 2013;11(1):1-18.
[58] Abreu MM, Danowski A, Wahl DG, Amigo M-C, Tektonidou M, Pacheco MS, et al. The relevance of “non-criteria” clinical manifestations of antiphospholipid syndrome: 14th international congress on antiphospholipid antibodies technical task force report on antiphospholipid syndrome clinical features. Autoimmunity reviews. 2015;14(5):401-14.
[59] Cook WA. Raynaud phenomenon in pregnancy. JAMA. 1976;235(2):145-6.
[60] Betelli M, Breda S, Ramoni V, Parisi F, Rampello S, Limonta M, et al. Pregnancy in systemic sclerosis. Journal of Scleroderma and Related Disorders. 2018;3(1):21-9.
[61] Ramoni V, Brucato A, Airò P, Bajocchi G, Bellisai F, Biasi D, et al. successful pregnancies but a higher risk of preterm births in patients with systemic sclerosis: an Italian multicenter study. 2012.
[62] Triggianese P, Conigliaro P, Chimenti MS, Barbato C, Greco E, Kroegler B, et al. Systemic Sclerosis: Exploring the Potential Interplay Between Thyroid Disorders and Pregnancy Outcome in an Italian Cohort. The Israel Medical Association Journal: IMAJ. 2017;19(8):473-7.
[63] Lidar M, Langevitz P. Pregnancy issues in scleroderma. Autoimmunity Reviews. 2012;11(6-7):A515-A9.
[64] Clark KE, Etomi O, Ong VH. Systemic sclerosis in pregnancy. Obstetric Medicine. 2020;13(3):105-11.
[65] Fredi M, Lazzaroni MG, Tani C, Ramoni V, Gerosa M, Inverardi F, et al. Systemic vasculitis and pregnancy: a multicenter study on maternal and neonatal outcome of 65 prospectively followed pregnancies. Autoimmunity reviews. 2015;14(8):686-91.
[66] Sangle SR, Vounotrypidis P, Briley A, Nel L, Lutalo PM, Sanchez-Fernandez S, et al. Pregnancy outcome in patients with systemic vasculitis: a single-centre matched case-control study. Rheumatology. 2015;54(9):1582-6.
[67] Pagnoux C, Le Guern V, Goffinet F, Diot E, Limal N, Pannier E, et al. Pregnancies in systemic necrotizing vasculitides: report on 12 women and their 20 pregnancies. Rheumatology. 2011;50(5):953-61.
[68] Machen L, Clowse ME. Vasculitis and pregnancy. Rheumatic Disease Clinics. 2017;43(2):239-47.
[69] Gatto M, Iaccarino L, Canova M, Zen M, Nalotto L, Ramonda R, et al. Pregnancy and vasculitis: a systematic review of the literature. Autoimmunity reviews. 2012;11(6-7):A447-A59.
[70] Debby A, Tanay A, Zakut H. Allergic granulomatosis and angiitis (Churg-Strauss vasculitis) in pregnancy. International archives of allergy and immunology. 1993;102(3):307-8.
[71] Comarmond C, Mirault T, Biard L, Nizard J, Lambert M, Wechsler B, et al. Takayasu arteritis and pregnancy. Arthritis & Rheumatology. 2015;67(12):3262-9.
[72] Tincani A, Dall'Ara F, Lazzaroni M, Reggia R, Andreoli L. Pregnancy in patients with autoimmune disease: a reality in 2016. Autoimmunity reviews. 2016;15(10):975-7.
[73] Hviid A, Mølgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. Cmaj. 2011;183(7):796-804.